000065618 001__ 65618
000065618 005__ 20240118091946.0
000065618 0247_ $$2doi$$a10.2741/4631
000065618 0248_ $$2sideral$$a104411
000065618 037__ $$aART-2018-104411
000065618 041__ $$aeng
000065618 100__ $$0(orcid)0000-0002-4665-9674$$aHerrera-Marcos, Luis V.$$uUniversidad de Zaragoza
000065618 245__ $$aPrenylcysteine oxidase 1, a pro-oxidant enzyme of low density lipoproteins
000065618 260__ $$c2018
000065618 5060_ $$aAccess copy available to the general public$$fUnrestricted
000065618 5203_ $$aElevated levels of low density lipoproteins (LDLs) cause atherosclerotic disease, and proteomic analyses have found that these lipoproteins are endowed with prenylcysteine lyase. This systematic review summarizes current understanding of this enzyme, now known as prenylcysteine oxidase 1 (PCYOX1), which hydrolyzes the thioether bond of prenylcysteines in the nal step in the degradation of prenylated proteins, releasing hydrogen peroxide, cysteine and the isoprenoid aldehyde. Despite the high variability of the PCYOX1 gene, no polymorphism
has yet been associated with any disease. The liver, which is responsible for vehiculization of the enzyme in lipoproteins, is one of the main organs responsible for its expression, together with the gastrointestinal tract, kidney, male reproductive tissue and muscle. Moreover, although hepatic mRNA expression is sensitive to diet and hormones, the repercussion of these changes in LDLs containing PCYOX1 has not been addressed. One consequence of its elevated activity could be an increase in hydrogen peroxide, which might help to propagate the oxidative burden of LDLs, thus making PCYOX1 a potential pharmacological target and a new biomarker in cardiovascular disease.
000065618 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B69$$9info:eu-repo/grantAgreement/ES/MINECO/SAF2013-41651-R$$9info:eu-repo/grantAgreement/ES/MINECO/SAF2016-75441-R
000065618 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000065618 590__ $$a2.214$$b2018
000065618 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b201 / 294 = 0.684$$c2018$$dQ3$$eT3
000065618 591__ $$aCELL BIOLOGY$$b144 / 191 = 0.754$$c2018$$dQ4$$eT3
000065618 592__ $$a0.908$$b2018
000065618 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2018$$dQ1
000065618 593__ $$aMedicine (miscellaneous)$$c2018$$dQ1
000065618 593__ $$aImmunology and Microbiology (miscellaneous)$$c2018$$dQ1
000065618 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000065618 700__ $$0(orcid)0000-0001-9578-6525$$aLou-Bonafonte, José M.$$uUniversidad de Zaragoza
000065618 700__ $$aMartínez-Gracia, María V.
000065618 700__ $$0(orcid)0000-0003-1197-4276$$aArnal, Carmen$$uUniversidad de Zaragoza
000065618 700__ $$0(orcid)0000-0002-0108-1004$$aNavarro, María A.$$uUniversidad de Zaragoza
000065618 700__ $$0(orcid)0000-0002-8251-8457$$aOsada, Jesús$$uUniversidad de Zaragoza
000065618 7102_ $$11005$$2410$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Fisiología
000065618 7102_ $$11009$$2773$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Sanidad Animal
000065618 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000065618 773__ $$g23 (2018), 1020-1037$$pFront. biosci.$$tFRONTIERS IN BIOSCIENCE$$x1093-9946
000065618 85641 $$uhttps://www.bioscience.org/2018/v23/af/4631/fulltext.htm$$zTexto completo de la revista
000065618 8564_ $$s305808$$uhttps://zaguan.unizar.es/record/65618/files/texto_completo.pdf$$yPostprint
000065618 8564_ $$s80046$$uhttps://zaguan.unizar.es/record/65618/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000065618 909CO $$ooai:zaguan.unizar.es:65618$$particulos$$pdriver
000065618 951__ $$a2024-01-18-09:10:39
000065618 980__ $$aARTICLE